Insider Transactions in Q4 2023 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2023
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
10,000
-21.14%
|
$730,000
$73.6 P/Share
|
|
Dec 27
2023
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.45%
|
$40,000
$4.44 P/Share
|
|
Dec 18
2023
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
2,458
-5.48%
|
$88,488
$36.34 P/Share
|
|
Dec 18
2023
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
13,020
+22.5%
|
$78,120
$6.72 P/Share
|
|
Dec 18
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$450,000
$36.95 P/Share
|
|
Dec 18
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Nov 30
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$400,000
$32.99 P/Share
|
|
Nov 30
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Nov 15
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$425,000
$34.57 P/Share
|
|
Nov 15
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Nov 09
2023
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,500
-1.63%
|
$87,500
$35.4 P/Share
|
|
Oct 30
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$400,000
$32.17 P/Share
|
|
Oct 30
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Oct 16
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$412,500
$33.7 P/Share
|
|
Oct 16
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Oct 12
2023
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,500
-1.61%
|
$87,500
$35.89 P/Share
|
|
Oct 06
2023
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
12,500
-2.75%
|
$375,000
$30.0 P/Share
|
|
Oct 06
2023
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+2.68%
|
$75,000
$6.67 P/Share
|
|
Oct 02
2023
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
448
+3.79%
|
$12,096
$27.88 P/Share
|
|
Oct 02
2023
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
448
+2.35%
|
$12,096
$27.88 P/Share
|
|
Oct 02
2023
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
448
+2.35%
|
$12,096
$27.88 P/Share
|
|
Oct 02
2023
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
448
+2.28%
|
$12,096
$27.88 P/Share
|
|
Oct 02
2023
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
762
+2.34%
|
$20,574
$27.88 P/Share
|
|
Oct 02
2023
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
224
+1.29%
|
$6,048
$27.88 P/Share
|